Navigation Links
SemBioSys announces second quarter 2008 financial and operational results
Date:8/5/2008

ss) 11,958 153,036 (66,707) 170,985

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

65,195 361,945 95,724 534,154

------------ ------------ ------------ ------------

Net loss and

comprehensive loss

for the period (6,414,856) (3,225,371) (11,431,911) (6,453,782)

Deficit - Beginning

of period (61,176,218) (43,968,897) (56,159,163) (40,740,486)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Deficit - End of

period (67,591,074) (47,194,268) (67,591,074) (47,194,268)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Loss per share -

basic and diluted (0.25) (0.15) (0.44) (0.31)

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

Weighted average

shares outstanding 25,937,476 22,089,356 25,936,634 20,511,557

------------ ------------ ------------ ------------

------------ ------------ ------------ ------------

SemBioSys Genetics Inc.

Consolidated Statements of Cash Flows

(Unaudited)

-------------------------------------------------------------------------

(expressed in Canadian dollars)

Three month period ended Six month period ended

June 30, June 30, June 30, June 30,

2008 2007
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... (PRWEB) August 21, 2014 On Wednesday of ... gel to use Redox Signaling molecules, became available for purchase ... overwhelming. , "The way that RENU 28 works is, if ... slowing down of the rate of cellular renewal within your ... the increasing of that rate of cellular renewal. What RENU ...
(Date:8/20/2014)... , Aug. 20, 2014 Neurotrope, Inc. ... a conference call to provide an update on ... Eastern daylight timeDial-in numbers:(888) 505-4369 (U.S. and Canada) ... web cast: www.neurotropebioscience.com , under "Investor Relations"The teleconference ... completion through September 2, 2014 at (888) 203-1112 ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
(Date:8/19/2014)... NJ (PRWEB) August 20, 2014 ... and regenerative medicine is an inadequate vascular supply. ... constructs and decellularized tissues is critical for successful ... have attempted to mitigate deficiencies in vascularization and ... adding scaffold bioactivity, optimizing scaffold design and architecture, ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Compound, 1-TDC, SAN DIEGO, Oct. 9 ... appointment of Dr. Thomas Van,Dyke to its Medical ... to,Imagenetix on their experimental compound, 1-TDC, for the ... is Professor, Department of,Periodontology and Oral Biology, Boston ...
... Oct. 9 BioElectronics,Corporation, (Pink Sheets: BIEL), ... has cleared ActiPatch for sale by its,distributor, ... that the experienced sales professionals of,Endotherapeutics will ... team has many decades of experience in ...
... Nanoscale devices present a unique challenge to any optical ... to travel in a straight line. , On the ... light between two surfaces very close together (sometimes as ... the light. Light behaves much differently on the nanoscale ...
Cached Biology Technology:Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 2Dr. Thomas Van Dyke Renowned Boston University Professor Joins Imagenetix's Medical Advisory Board 3Australian Therapeutics Goods Administration Approval for ActiPatch Achieved 2Taming tiny, unruly waves for nano optics 2
(Date:8/20/2014)... Huntsman Cancer Institute (HCI) at the University of Utah ... that encodes BCR-ABL, the unregulated enzyme driving the blood ... Cancer Society, nearly 6,000 new cases of CML will ... called tyrosine kinase inhibitors (TKIs), target BCR-ABL and are ... CML but control it in a way that allows ...
(Date:8/20/2014)... image of the Para and Mato Grosso states of ... set in order to deforest the land. Deforestation is ... where the land is thereafter converted to a nonforest ... farms, ranches, or urban use. The herringbone-patterned tan lines ... in the middle of the image are evidence of ...
(Date:8/20/2014)... Cancer Research UK scientists have discovered that acral melanomas ... Bob Marley,s death are genetically distinct from other more ... is external) published in the journal Pigment Cell & ... palms of the hands, soles of the feet, nail-beds and ... types of melanoma, it,s not caused by UV damage from ...
Breaking Biology News(10 mins):Blueprint for next generation of chronic myeloid leukemia treatment 2Scientists learn more about rare skin cancer that killed Bob Marley 2
... -- A few came. They ran. They left. As a ... training in 2008 in new running suits chosen after tests ... The experience was enough to make both the University ... unaware that it was InSport,s training clothes that they had ...
... A new book by researchers at the Hebrew ... mouse demonstrates a surprising similarity between mice and humans. ... a team from the Hebrew University Bone Laboratory consisting of ... and Dr. Yankel Gabet. Also participating in the writing of ...
... YORK (October 9, 2007) -- When its time for ... they head to where it is safest from predators ... study by the Wildlife Conservation Society. Published in ... that moose avoid predation of their calves by grizzly ...
Cached Biology News:Marines land at UO, leave with plans to wear Oregon-made training suits 2Marines land at UO, leave with plans to wear Oregon-made training suits 3Of mice and men: similarities between skeletons of both 2
...
SAPK/JNK Antibody...
Molecular Biology grade. Ideally suited for DNA and RNA separation and recovery. High gel strength. Gelling temp. 36C. Melting temp. 88C. EEO: 0.05-0.13 Resolution 0.2-40 kb; Rnase/Dnase: none detec...
Component in MasterPure™ Purification Kits...
Biology Products: